Neuroprotective activity of JM-20 in preclinical models of Parkinson's disease
Keywords:
α-synuclein; mitochondrial dysfunction; Parkinson's disease; oxidative stress and JM-20Abstract
Introduction: JM-20 is a hybrid molecule obtained through chemical synthesis, which has undergone several preclinical trials that validate its therapeutic potential as a disease-modifying drug for Parkinson's disease. The complexity and multiplicity of the pathophysiological events associated with this disease are at the heart of the challenges posed by the development of effective treatments that reverse, halt, or slow the course of neurodegeneration.
Objective: To show the basis for the development of a new therapeutic candidate for patients with Parkinson's disease.
Methods: In vitro, in silico and in vivo studies, as well as a correlation between morphological and molecular variables with motor behavior were carried out to evaluate the effect of JM-20 on α-synuclein and in models of neurotoxin-induced parkinsonism.
Results: The results showed a clear protective effect of JM-20 in different cellular models related to Parkinson's disease. In addition, in silico docking and dynamics studies demonstrated that JM-20 interacts with α-synuclein, inducing the formation of non-toxic oligomers of the protein. In animal models, JM-20, at oral doses of 40 mg/kg, prevented the behavioral damage characteristic of the neurotoxic models used. Furthermore, ex vivo studies in rat brains confirmed that intragastric administration of JM-20 improved oxidative parameters in the substantia nigra and striatum.
Conclusions: This review provides pharmacological evidence of the neuroprotective activity of this new molecule, supporting its usefulness for the development of new anti-Parkinson's drugs.
Downloads
References
1. Zaman V, Shields DC, Shams R, Drasites KP, Matzelle D, Haque A, et al. Cellular and molecular pathophysiology in the progression of Parkinson's disease. Metab Brain Dis. 2021;36(5):815-27. Disponible en: https://doi.org/10.1007/s11011-021-00689-5
2. Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson's disease. Lancet. 2024;403(10423):293-304. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/38245249
3. Hoglinger G, German Parkinson's Guidelines C, Trenkwalder C. Diagnosis and treatment of Parkinson s disease (guideline of the German Society for Neurology). Neurological Research and Practice. 2024;6(1):30. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/38845028
4. García-Beltrán O, Urrutia PJ, Núñez MT. On the Chemical and Biological Characteristics of Multifunctional Compounds for the Treatment of Parkinson Disease. Antioxidants (Basel). 2023;12(2):214. Disponible en: https://www.mdpi.com/2076-3921/12/2/214
5. Cheong SL, Federico S, Spalluto G, Klotz KN, Pastorin G. The current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapy. Drug Discovery Today. 2019;24(9):1769-83. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31102728
6. Banjare P, Wamanrao Matore B, Murmu A, Kumar V, Singh J, Roy PP. In silico Strategy: A Promising Implement in the Development of Multitarget Drugs against Neurodegenerative Diseases. Current Topics in Medicinal Chemistry. 2023;23(29):2765-91. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/37723952
7. Sanghai N, Vuong B, Burak Berk A, Afridi MSK, Tranmer GK. Current Small Molecule-Based Medicinal Chemistry Approaches for Neurodegeneration Therapeutics. ChemMedChem 2024;19(9):e202300705. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/38329887
8. Nunez-Figueredo Y, Rodriguez EO, Reyes YV, Dominguez CC, Parra AL, Sanchez JR, et al. Characterization of the anxiolytic and sedative profile of JM-20: a novel benzodiazepine-dihydropyridine hybrid molecule. Neurol Res. 2013;35(8):804-12. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23651620
9. Nunez-Figueredo Y, Pardo Andreu GL, Oliveira Loureiro S, Ganzella M, Ramirez-Sanchez J, Ochoa-Rodriguez E, et al. The effects of JM-20 on the glutamatergic system in synaptic vesicles, synaptosomes and neural cells cultured from rat brain. Neurochem Int. 2015;81:41-7. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/25617730
10. Nunez-Figueredo Y, Pardo-Andreu GL, Ramirez-Sanchez J, Delgado-Hernandez R, Ochoa-Rodriguez E, Verdecia-Reyes Y, et al. Antioxidant effects of JM-20 on rat brain mitochondria and synaptosomes: mitoprotection against Ca(2)(+)-induced mitochondrial impairment. Brain Res Bull. 2014;109:68-76 Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/25305343
11. Nunez-Figueredo Y, Ramirez-Sanchez J, Hansel G, Simoes Pires EN, Merino N, Valdes O, et al. A novel multi-target ligand (JM-20) protects mitochondrial integrity, inhibits brain excitatory amino acid release and reduces cerebral ischemia injury in vitro and in vivo. Neuropharmacology. 2014;85:517-27. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24953828
12. Nunez-Figueredo Y, Ramirez-Sanchez J, Delgado-Hernandez R, Porto-Verdecia M, Ochoa-Rodriguez E, Verdecia-Reyes Y, et al. JM-20, a novel benzodiazepine-dihydropyridine hybrid molecule, protects mitochondria and prevents ischemic insult-mediated neural cell death in vitro. Eur J Pharmacol. 2014;726:57-65. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24462350
13. Ramirez-Sanchez J, Simoes Pires EN, Nunez-Figueredo Y, Pardo-Andreu GL, Fonseca-Fonseca LA, Ruiz-Reyes A, et al. Neuroprotection by JM-20 against oxygen-glucose deprivation in rat hippocampal slices: Involvement of the Akt/GSK-3beta pathway. Neurochem Int. 2015;90:215-23. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26361722
14. Ramírez-Sánchez J, Pires ENS, Meneghetti A, Hansel G, Nuñez-Figueredo Y, Pardo-Andreu GL, et al. JM-20 Treatment After MCAO Reduced Astrocyte Reactivity and Neuronal Death on Peri-infarct Regions of the Rat Brain. Mol Neurobiol. 2019;56(1):502-12. DOI: 10.1007/s12035-018-1087-8.
15. Santos CC, Cardim-Pires TR, Shvachiy L, Fonseca-Fonseca LA, Munoz P, Almeida A, et al. JM-20, a Benzodiazepine-Dihydropyridine Hybrid Molecule, Inhibits the Formation of Alpha-Synuclein-Aggregated Species. Neurotox Res. 2022;40(6):2135-47 Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/35997936
16. Wong-Guerra M, Jimenez-Martin J, Fonseca-Fonseca LA, Ramirez-Sanchez J, Montano-Peguero Y, Rocha JB, et al. JM-20 protects memory acquisition and consolidation on scopolamine model of cognitive impairment. Neurol Res. 2019;41(5):385-98 Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/30821663
17. Wong-Guerra M, Montano-Peguero Y, Ramirez-Sanchez J, Jimenez-Martin J, Fonseca-Fonseca LA, Hernandez-Ensenat D, et al. JM-20 treatment prevents neuronal damage and memory impairment induced by aluminum chloride in rats. Neurotoxicology. 2021;87:70-85. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/34481871
18. Furtado ABV, Gonçalves DF, Hartmann DD, Courtes AA, Cassol G, Nunez-Figueredo Y, et al. JM-20 Treatment After Mild Traumatic Brain Injury Reduces Glial Cell Pro-inflammatory Signaling and Behavioral and Cognitive Deficits by Increasing Neurotrophin Expression. Molecular Neurobiology. 2021;58(9):4615-27. DOI: 10.1007/s12035-021-02436-4.
19. Coelho-Cerqueira E, Carmo-Goncalves P, Pinheiro AS, Cortines J, Follmer C. alpha-Synuclein as an intrinsically disordered monomer--fact or artefact? FEBS J. 2013;280(19):4915-27 Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23927048
20. Palhano FL, Leme LP, Busnardo RG, Foguel D. Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases. J Biol Chem. 2009;284(3):1443-53. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/18984591
21. Santos CC, Araujo FM, Ferreira RS, Silva VB, Silva JHC, Grangeiro MS, et al. Aminochrome induces microglia and astrocyte activation. Toxicol In Vitro. 2017;42:54-60 Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28392416
22. Fonseca-Fonseca LA, da Silva VDA, Wong-Guerra M, Ramirez-Sanchez J, Yaquis ASP, Ochoa-Rodriguez E, et al. JM-20 protects against 6-hydroxydopamine-induced neurotoxicity in models of Parkinson's disease: Mitochondrial protection and antioxidant properties. Neurotoxicology. 2021;82:89-98. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/33232743
23. Fonseca-Fonseca LA, Wong-Guerra M, Ramirez-Sanchez J, Montano-Peguero Y, Padron Yaquis AS, Rodriguez AM, et al. JM-20, a novel hybrid molecule, protects against rotenone-induced neurotoxicity in experimental model of Parkinson's disease. Neurosci Lett. 2019;690:29-35 Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/30304707
24. Fahrrolfes R, Bietz S, Flachsenberg F, Meyder A, Nittinger E, Otto T, et al. ProteinsPlus: a web portal for structure analysis of macromolecules. Nucleic Acids Res. 2017;45(W1):W337-W43 Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28472372
25. Anastassova N, Aluani D, Hristova-Avakumova N, Tzankova V, Kondeva-Burdina M, Rangelov M, et al. Study on the Neuroprotective, Radical-Scavenging and MAO-B Inhibiting Properties of New Benzimidazole Arylhydrazones as Potential Multi-Target Drugs for the Treatment of Parkinson's Disease. Antioxidants (Basel). 2022;11(5):884. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/35624746
26. Makhoba XH, Viegas CJr, Mosa RA, Viegas FPD, Pooe OJ. Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases. Drug design, development and therapy. 2020;14:3235-49. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/32884235
27. Calabresi P, Di Filippo M. Multitarget disease-modifying therapy in Parkinson's disease? The Lancet Neurology. 2015;14(10):975-6. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26376965
28. Nunez-Figueredo Y, Ramírez-Sanchez J, Hansel G, Pardo-Andreu GL, Merino N, Aparicio G, et al. Therapeutic potential of the novel hybrid molecule JM-20 against focal cortical ischemia in rats. Journal of Pharmacy & Pharmacognosy Research. 2016;4(4):153-8. Disponible en: https://doi.org/10.56499/jppres16.126_4.4.153
29. Fernandes L, Messias B, Pereira-Neves A, Azevedo EP, Araujo J, Foguel D, et al. Green Tea Polyphenol Microparticles Based on the Oxidative Coupling of EGCG Inhibit Amyloid Aggregation/Cytotoxicity and Serve as a Platform for Drug Delivery. ACS Biomater Sci Eng. 2020;6(8):4414-23. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/33455167
30. Liani E, Eyal A, Avraham E, Shemer R, Szargel R, Berg D, et al. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc Natl Acad Sci U S A. 2004;101(15):5500-5. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/15064394
31. Gupta E, Gupta S, Kumar A, Kulshrestha A, Niraj R, Niraj K. Molecular Docking Study to Identify Potent Inhibitors of Alpha- synuclein Aggregation of Parkinson's Disease. International Journal of Contemporary Medical Research. 2019;6. DOI:10.21276/ijcmr.2019.6.11.25.
32. Diaz-Araya G, Godoy L, Naranjo L, Squella JA, Letelier ME, Nunez-Vergara LJ. Antioxidant effects of 1,4-dihydropyridine and nitroso aryl derivatives on the Fe+3/ascorbate-stimulated lipid peroxidation in rat brain slices. General Pharmacology. 1998;31(3):385-91. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/9703206
33. Yanez C, Lopez-Alarcon C, Camargo C, Valenzuela V, Squella JA, Nunez-Vergara LJ. Structural effects on the reactivity 1,4-dihydropyridines with alkylperoxyl radicals and ABTS radical cation. Bioorganic & Medicinal Chemistry. 2004;12(9):2459-68 Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/15080941
34. Babazadeh A, Vahed FM, Liu Q, Siddiqui SA, Kharazmi MS, Jafari SM. Natural Bioactive Molecules as Neuromedicines for the Treatment/Prevention of Neurodegenerative Diseases. ACS Omega. 2023;8(4):3667-83 Disponible en: https://doi.org/10.1021/acsomega.2c06098
35. Ioghen OC, Ceafalan LC, Popescu BO. SH-SY5Y Cell Line In Vitro Models for Parkinson Disease Research Old Practice for New Trends. Journal of Integrative Neuroscience. 2023;22(1) Disponible en: https://www.imrpress.com/JIN/articles/10.31083/j.jin2201020
36. Khan T, Waseem R, Zehra Z, Aiman A, Bhardwaj P, Ansari J, et al. Mitochondrial Dysfunction: Pathophysiology and Mitochondria-Targeted Drug Delivery Approaches. Pharmaceutics. 2022;14(12):2657. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/36559149
37. Dai Y, Wang H, Lian A, Li J, Zhao G, Hu S, et al. A comprehensive perspective of Huntington’s disease and mitochondrial dysfunction. Mitochondrion. 2023;70:8-19. Disponible en: https://www.sciencedirect.com/science/article/pii/S1567724923000272
38. Glinka YY, Youdim MB. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. European journal of pharmacology. 1995;292(3-4):329-32. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/7796873
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Luis Arturo Fonseca Fonseca, Nancy Pavón Fuentes , Jeney Ramírez Sánchez, Alejandro Saúl Padrón Yaquis , Tiago Fleming Outeiro, Estael Ochoa Rodríguez , Yamila Verdecia Reyes , Abel Mondenlo Rodríguez , Víctor Diogenes Amaral da Silva , Silvia Lima Costa , Yanier Núñez Figueredo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The journal Anales de la Academia de Ciencias de Cuba protects copyright, and operates with a Creative Commons License 4.0 (Creative Commons Attribution-NonCommercial License 4.0). By publishing in it, authors allow themselves to copy, reproduce, distribute, publicly communicate their work and generate derivative works, as long as the original author is cited and acknowledged. They do not allow, however, the use of the original work for commercial or lucrative purposes.
The authors authorize the publication of their writings, retaining the authorship rights, and assigning and transferring to the magazine all the rights protected by the intellectual property laws that govern in Cuba, which imply editing to disseminate the work.
Authors may establish additional agreements for the non-exclusive distribution of the version of the work published in the journal (for example, placing it in an institutional repository or publishing it in a book), with recognition of having been first published in this journal.
To learn more, see https://creativecommons.org
